TSE:FRX - Fennec Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$12.24 0.00 (0.00 %)
(As of 07/20/2018 04:00 PM ET)
Previous CloseC$12.24
Today's RangeC$12.24 - C$12.24
52-Week RangeC$7.10 - C$18.86
VolumeN/A
Average Volume3,068 shs
Market CapitalizationC$218.17 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Receive FRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolTSE:FRX
CUSIPN/A
Phone+1-919-6364530

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-101.78%
Return on Assets-93.65%

Miscellaneous

EmployeesN/A
Outstanding Shares18,495,000
Market CapC$218.17

Fennec Pharmaceuticals (TSE:FRX) Frequently Asked Questions

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "FRX."

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (TSE:FRX) announced its earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06. View Fennec Pharmaceuticals' Earnings History.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for Fennec Pharmaceuticals.

What price target have analysts set for FRX?

3 brokers have issued 12-month price objectives for Fennec Pharmaceuticals' stock. Their predictions range from C$22.00 to C$22.00. On average, they anticipate Fennec Pharmaceuticals' share price to reach C$22.00 in the next twelve months. This suggests a possible upside of 79.7% from the stock's current price. View Analyst Ratings for Fennec Pharmaceuticals.

What is the consensus analysts' recommendation for Fennec Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Fennec Pharmaceuticals' key competitors?

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the folowing people:
  • Mr. Rostislav Raykov, CEO & Director (Age 42)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 64)

Has Fennec Pharmaceuticals been receiving favorable news coverage?

Media coverage about FRX stock has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fennec Pharmaceuticals earned a news sentiment score of 0.15 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 45.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FRX stock can currently be purchased for approximately C$12.24.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of C$218.17 million.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company can be reached via phone at +1-919-6364530.


MarketBeat Community Rating for Fennec Pharmaceuticals (TSE FRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.